BACKGROUND
The risk of transmission of HSV during pregnancy is related to the timing of
maternal infection and whether an outbreak is a primary episode, nonprimary
first episode, or recurrent first episode.Most
cases of neonatal herpes are acquired during exposure to HSV during delivery.
The greatest risk to the newborn occurs when symptomatic primary infection
occurs during the last trimester.
- For primary infection the transmission rate is 30 -50 %.
- For a nonprimary first episode the transmission rate is 33%.
- For a symptomatic recurrence the transmission rate is 3%.
RECOMMENDATIONS
- Viral cultures at the time of labor not recommended.
- Patients with
primary HSV during pregnancy should be treated with Acyclovir
400mg TID for 7 -10 days or
200 mg 5 times a day for 7 -10 days.
- In patients with recurrent episodes consider Acyclovir 200 mg QID or 400 mg TID
beginning at 36 weeks to
try to prevent an outbreak at the time of labor.
- A thorough speculum exam should be performed at the time of labor to identify
any lesions.
- Cesarean delivery is advised for women with active genital or prodromal symptoms
at the time of
labor .
- Cesarean delivery is not recommended for women with active nongenital lesions.
The latter should be covered and the patient allowed to deliver vaginally.
- The patient should be advised that C/S does not eliminate the risk of transmission
to the infant.
- The pediatrician should be informed of the maternal
herpes history.
REFERENCES
American College of Obstetricians and Gynecologists. Management of Herpes in
Pregnancy. Practice Bullentin #8 WashingtoR DC: American College of
Obstetricians and Gynecologists; 1999.
Scott LL, et al. Acyclovir suppression to prevent recurrent genital herpes at
delivery. Infect Dis Obstet Gynecol.2001:9.1-7.
Scott LL, et al. Acyclovir suppression to prevent clinical recurrences at
delivery after fist episode gelrital herpes in pregnancy: An open label trial.
Infect Dis Obstet G}Tnecol. 2001;9:75-80.
Created: 3/1/2003 M Hellen Rodriguez, M.D
Updated: 3/1/2003 M Hellen Rodriguez, M.D
|